严重急性呼吸综合征2019(sever acute respiratory syndrome，SARS)、中东呼吸综合征(Middle East respiratory syndrome，MERS)和2019冠状病毒病(corona virus disease 2019，COVID-19)对全世界人民造成了严重的经济损失和精神伤害。鉴于SARS再无新发病例，研究进展少，本文着重介绍MERS和COVID-19的治疗。MERS和COVID-19的治疗大同小异，曾在临床使用核苷类似物、洛匹那韦/利托那韦、中和抗体、糖皮质激素及其他潜在疗法(旧药新用)。因COVID-19流行范围广，感染人数多，涌现出一些新药，例如瑞德西韦、REGN-CoV2抗体、LY-CoV555抗体等，但目前效果仍欠佳，临床诊疗方案也尚待完善。本文就SARS、MERS和COVID-19治疗的研究进展进行综述，为进一步研究其治疗方案、提高治疗效果进而降低病死率提供理论基础。

Severe acute respiratory syndrome (sever acute respiratory syndrome, SARS), Middle East respiratory syndrome (middle east respiratory syndrome, MERS), and new coronavirus pneumonia (corona virus disease 2019, COVID-19) have brought serious illnesses to people all over the world. Economic loss and mental injury, given that there are no new cases of SARS and little progress in research, this article focuses on the treatment of MERS and COVID-19. The treatments of MERS and COVID-19 are similar. Nucleoside analogs, lopinavir/ritonavir, neutralizing antibodies, glucocorticoids, and other potential therapies (new use of old drugs) have been used clinically. Due to the wide spread of COVID-19 and the large number of infected people, some new drugs have emerged, such as Remdesivir, REGN-COV2 antibody, LY-CoV555 antibody, etc., but the current effect is not good, and the clinical diagnosis and treatment plan has yet to be improved. This article reviews the research progress in the treatment of SARS, MERS and COVID-19, and provides a theoretical basis for further research on their treatment options, improving treatment effects, and reducing mortality.